Happi Staff08.13.20
In July, the Environmental Protection Agency (EPA) finalized its risk evaluation for methylene chloride. The methylene chloride risk evaluation contains the agency’s final determinations on which conditions of use present unreasonable risks to human health or the environment based on a robust review of the scientific data.
As required by the Toxic Substances Control Act (TSCA) section 6(c)(1), the EPA will initiate TSCA section 6(a) risk management actions for the conditions of use (COU) that were identified to present an unreasonable risk.
The EPA recently reached out to HCPA to identify and speak with companies that are impacted by the risk evaluation/risk management of methylene chloride. The tentative plan is for the EPA to host a conference call or webinar to provide an overview of risk management and address questions by interested parties, as well as hold one-on-one conversations to inform the risk management process and identify critical uses of methylene chloride that should be considered. Moving forward, additional chemicals that require risk management will most likely follow a similar process.
If you would like to be involved as an interested party, contact Dr. Steve Bennett, senior vice president, scientific & regulatory affairs.
As required by the Toxic Substances Control Act (TSCA) section 6(c)(1), the EPA will initiate TSCA section 6(a) risk management actions for the conditions of use (COU) that were identified to present an unreasonable risk.
The EPA recently reached out to HCPA to identify and speak with companies that are impacted by the risk evaluation/risk management of methylene chloride. The tentative plan is for the EPA to host a conference call or webinar to provide an overview of risk management and address questions by interested parties, as well as hold one-on-one conversations to inform the risk management process and identify critical uses of methylene chloride that should be considered. Moving forward, additional chemicals that require risk management will most likely follow a similar process.
If you would like to be involved as an interested party, contact Dr. Steve Bennett, senior vice president, scientific & regulatory affairs.
